Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delgocitinib cream in active discoid lupus erythematosus
2018-003615-22Phase 2Terminated
- Sponsor
- LEO Pharma
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of delgocitinib in discoid lupus erythematosus (DLE), sponsored by LEO Pharma. Primary endpoint: Target lesion IGA response at Week 6. Started Mar 2019; status: terminated.
02
Drugs
delgocitinib
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2018-003615-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003615-22.